Enhanced cd48-targeted Cellular Immunotherapy

Mandelboim Ofer, HUJI, School of Medicine - IMRIC, Immunology and Cancer Research


Life Sciences and Biotechnology   


Immunotherapy, Cancer


Human natural killer cells (NKs) are part of the innate immune system and can recognized CD48, which was found to be overexpressed by a variety of cancer types. Existing therapies based on primary NK cells are limited by donor availability and short ex-vivo lifespan.

We develop human NK lines which can be grown limitlessly and inexpensively, contributing in the regulation pathway of CD48. Thus, we will reach therapeutic effect with no extra risk of side effects.


Contact for more information:

Keren-Or Amar
VP, Business Development, Healthcare
Contact ME: